Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 1998, p. 362-368, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Doxycycline Hyclate Treatment of Experimental
Canine Ehrlichiosis Followed by Challenge Inoculation with Two
Ehrlichia canis Strains
Edward B.
Breitschwerdt,*
Barbara C.
Hegarty, and
Susan
I.
Hancock
Department of Companion Animal and Special
Species Medicine, College of Veterinary Medicine, North Carolina
State University, Raleigh, North Carolina 27606
Received 5 June 1997/Returned for modification 25 September
1997/Accepted 10 November 1997
 |
ABSTRACT |
Dogs were experimentally inoculated with Ehrlichia
canis Florida to assess the efficacy of doxycycline hyclate for
the treatment of acute ehrlichiosis. Treatment with doxycycline
eliminated infection in eight of eight dogs. Untreated infected control
dogs appeared to eliminate the infection or, alternatively, suppress
the degree of ehrlichiemia to a level not detectable by tissue culture
isolation or PCR or by transfusion of blood into recipient dogs. Prior
infection did not infer protection against homologous (strain Florida)
or heterologous (strain NCSU Jake) strains of E. canis. We
conclude that doxycycline hyclate is an effective treatment for acute
E. canis infection; however, these results may not be
applicable to chronic infections in nature. Spontaneous resolution of
infection, induced by the dog's innate immune response, provides
evidence that an E. canis vaccine, once developed, might
potentially confer protective immunity against the organism.
 |
INTRODUCTION |
Ehrlichia canis is a
cause of monocytic ehrlichiosis, a disease of worldwide importance in
dogs. Despite several studies that have addressed the therapeutic
efficacy of tetracycline hydrochloride (1, 2, 6, 17) or
doxycycline hyclate (2, 11, 19, 20) for the treatment of
E. canis infection in dogs, the effectiveness of
tetracycline derivatives for the elimination of E. canis
infection remains controversial. In an experimental infection study,
treatment with doxycycline hyclate for 7 days resulted in a carrier
status, i.e., E. canis organisms were still present, in
three of five dogs (11). As a result of this and because of
persistent posttreatment clinical or hematologic abnormalities or the
persistence of E. canis-specific serum antibodies, some
veterinarians have adopted the practice of treating E. canis
infections with doxycycline for months or years (2).
Providing medically or scientifically valid documentation that E. canis infection has been therapeutically eliminated has important
clinical implications. This documentation is particularly relevant for
dogs with persistent unexplained clinical or hematologic abnormalities
following treatment for ehrlichiosis (nonresponders).
Recently, important strain differences have been identified among other
Ehrlichia species, particularly Ehrlichia
chaffeensis and Ehrlichia risticii (4, 7, 8,
21). Differences in in vitro biologic behaviors and
antigenicities were found for the two currently characterized E. chaffeensis strains (8). Of particular importance,
E. risticii antigenic strain differences appear to be
responsible for the failure of commercially available vaccines to
consistently prevent Potomac horse fever (4, 21). Despite
substantial variation in the type, duration, or severity of disease
manifestations attributed to natural E. canis infection, there is minimal clinical, experimental, or microbiologic data to
compare the immunopathogenic variability associated with different E. canis strains (16). The extent to which
differences in disease manifestations reflect pathogenic diversity
among strains, variability in the immunologic response of individual
dogs to the rickettsia, repeated exposure to E. canis,
coinfection with other tick-transmitted pathogens, or other, unknown
factors remains unclear. Although experimental studies conducted nearly
three decades ago documented reinfection following homologous E. canis challenge (3), studies using more sensitive
techniques for the detection of E. canis have not been
conducted to determine whether reinfection occurs following homologous
or heterologous E. canis challenge.
The purposes of this study were (i) to assess the efficacy of
doxycycline hyclate for the treatment of acute ehrlichiosis in
experimentally infected dogs; (ii) to compare the utility of tissue
culture isolation, Western immunoblotting, PCR detection of E. canis DNA, and the transfusion of blood into recipient dogs to
document therapeutic elimination of the organism; and (iii) to compare
the severity of disease manifestations following homologous or
heterologous E. canis challenge.
 |
MATERIALS AND METHODS |
E. canis strains.
E. canis Florida, the
historical reference strain, was obtained in primary canine monocytes
from the University of Illinois before 1988. The North Carolina isolate
(NCSU Jake) was cultured in 1989 from a sick 2-year-old male pug dog
admitted to the North Carolina State University Veterinary Teaching
Hospital for evaluation of normocytic normochromic nonregenerative
anemia (hematocrit, 20%), neutropenia (2,600 neutrophils/µl),
thrombocytopenia (platelets 29,000/µl), and seroreactivity to
E. canis antigen (reciprocal immunofluorescent antibody
[IFA] titer, 20,840). E. canis NCSU Jake has been
maintained in tissue culture since the original isolation and was used
for heterologous challenge in this study.
Inoculum preparation.
E. canis organisms (Florida and
NCSU Jake strains) were grown in 030 cells (a continuous canine-origin
histiocytic cell line) (15). Aliquots of frozen cellular
stock were assayed for viable organisms with 10-fold serial dilutions
in tubes containing 030 cells. The cellular harvests were diluted to
100 organisms/ml in sterile brain heart infusion broth and were
inoculated intravenously into two dogs (donor 1 received 10 ml, but
donor 2 received only 2 ml due to the development of anaphylaxis) that
served as infected-blood donors for the experimental infection study.
Infection of donor dogs with the tissue culture-derived E. canis strains was timed so that experimental recipients were
transfused during a period of culture-confirmed ehrlichiemia. Infected
blood was collected from donor 1 on postinfection day (PID) 33 for
initial infection of dogs in groups II, III, and IV and on PID 103 for
homologous challenge of dogs in group III. Blood from donor 2 was
collected on PID 25 for heterologous challenge of dogs in group IV.
Ehrlichiemia was documented by tissue culture isolation on PIDs 33 and
103 for donor 1 and on PID 25 for donor 2.
Experimental animals and infection transmission.
Sixteen
mixed-breed dogs (Hazelton Laboratories) ranging in age from 9 to 12 months were randomized to one of the following four study groups: group
I, uninfected control; group II, infected control; group III,
homologous challenge; group IV, heterologous challenge
(n = 4 dogs/group). Prior to infection, clinical and hematologic test results were within the reference ranges, and all dogs
were seronegative for E. canis antigens by IFA testing. Initially, groups II, III, and IV were inoculated with 20 ml of E. canis reference strain (strain Florida)-infected donor
blood anticoagulated with citrate dextrose solution (ACD) at a ratio of
1 ml of ACD/20 ml of blood. The uninfected control group (group I) was
inoculated by the same procedure with 20 ml of blood from a healthy
donor.
Doxycycline treatment.
Beginning on PID 31, group III and IV
dogs were treated with oral doxycycline hyclate (mean group dosages, 6 and 5.6 mg/kg of body weight twice daily, respectively) for 14 consecutive days. Group II dogs, although infected, were not treated
with doxycycline.
Challenge inoculation.
On PID 90, group III dogs received a
homologous E. canis challenge (strain Florida) and group IV
dogs received a heterologous E. canis challenge (strain NCSU
Jake). Group I and II dogs received blood from a healthy donor not
seroreactive for E. canis.
Monitoring.
Beginning 1 week prior to initial inoculation,
physical examinations, including rectal temperature measurements and
quantitation of behavioral characteristics, were performed daily in an
examiner-blinded fashion. Behavioral scores were recorded by using the
following criteria: 5, alert, active, and eating; 4, alert, inactive,
and eating; 3, depressed, inactive, and anorexic; 2, severely depressed and anorexic; and 1, recumbent. Beginning on PID 7, blood samples were
collected from the jugular vein at approximately 7-day intervals until
the conclusion of the study at 21 weeks.
Blood for complete blood cell counts, manual thrombocyte counts, and
PCR analyses was collected in tubes containing EDTA. Serum for E. canis IFA testing and Western immunoblotting was separated from
tubes not containing an anticoagulant.
Serology.
A microimmunofluorescence test was used to detect
antibodies to E. canis Florida on 30-well Teflon-coated
slides (19). Serial twofold dilutions of sera from the dogs
were reacted with fluorescein isothiocyanate anti-canine immunoglobulin
G conjugate (Organon Teknika, Westchester, Pa.). Endpoint titers were
determined as the last dilution at which brightly staining organisms
could be detected on a fluorescence microscope with exciter and barrier filters.
Documenting therapeutic elimination of E. canis.
Four techniques for documenting therapeutic elimination of E. canis were compared: tissue culture isolation, Western
immunoblotting, PCR detection of E. canis DNA, and
transfusion of blood into recipient dogs.
(i) Tissue culture isolation.
Isolation in tissue culture
was performed by a modification of the method described by Iqbal and
Rikihisa (11). For each of the 16 dogs, 6 ml of blood was
collected aseptically from the jugular vein and placed into tubes
containing EDTA anticoagulant. Whole blood was spun at 1,500 × g for 5 min, the erythrocyte fraction was discarded, and the
plasma was spun again for 20 min. Leukocyte cell pellets were
resuspended in phosphate-buffered saline (PBS)-bovine serum albumin.
These suspensions were overlaid over 2 ml of Histopaque-1077 (Sigma,
St. Louis, Mo.) and spun at 2,000 × g for 15 min. The resulting monocyte-rich cell fractions were inoculated onto cultures of
030 cells in 24-well plates in duplicate and fed RPMI 1640 (Gibco BRL,
Gaithersburg, Md.) containing 20% fetal bovine serum (Hyclone, Logan,
Utah), L-glutamine, and sodium bicarbonate. The plates were
incubated at 35°C with 5% CO2 for 8 weeks. Cellular samples of culture supernatants were tested every 2 weeks by indirect immunofluorescence (with a monoclonal antibody provided by D. H. Walker, University of Texas Medical Branch, Galveston, Tex.) and direct
immunofluorescence (with rabbit anti-ehrlichia fluorescein isothiocyanate-labeled conjugate obtained from J. E. Dawson,
Centers for Disease Control and Prevention, Atlanta, Ga.) for the
presence of morulae. Testing prior to 4 weeks can result in occasional nonspecific staining of monocytoid cells. Therefore, to be considered positive, morulae had to be detected on two occasions after 4 weeks in
culture. Cultures were maintained for 8 weeks before they were
considered negative. Failure of cells to persist in culture for at
least 6 weeks was reported as an inconclusive result.
(ii) Western immunoblotting.
Antigen grown in 030 cells was
purified by sucrose gradient centrifugation, and the protein
concentration was determined. Dilutions made in final sample buffer at
a protein concentration of 2.5 mg/ml were loaded at 10 µl per well
and were electrophoresed on sodium dodecyl sulfate-polyacrylamide
precast minigels (Jule, Inc., New Haven, Conn.). Proteins were
electrotransferred to 0.45-µm-pore-size nitrocellulose paper. After
blocking with 5% milk in PBS, proteins were reacted with canine serum
samples at a 1:100 dilution followed by reaction with
peroxidase-conjugated goat anti-canine immunoglobulin G at a 1:400
dilution in 1% milk in PBS. Bands were detected with the color reagent
4-chloro-1-naphthol. Serum from a dog experimentally infected with
E. canis Florida with a reciprocal titer of 10,240 was used
as a positive control. Serum from uninfected laboratory-raised dogs was
reacted with E. canis and normal cell antigens to eliminate the possibility of nonspecific binding.
(iii) DNA extraction and nested PCR analysis.
With a
commercially available QIAmp Blood Kit (Qiagen, Chatsworth, Calif.),
DNA was extracted from 600-µl, EDTA-anticoagulated whole blood
samples that had been stored frozen at
70°C. Cell culture-grown
E. canis NCSU Jake was used as a positive control. A
two-step seminested PCR method was established by using three primers
(the primer sequences for the nested PCR used in this study were
recommended by S.-M. Chen, University of Texas Medical Branch) derived
from the 16S rRNA gene sequence of E. canis (8). The first PCR amplification was performed in a 50-µl reaction mixture
containing 1 µg of DNA template; 200 µM (each) dATP, dTTP, dCTP,
and dGTP; 10 pmol of primers designated GE2f
(5'-GTTAGTGGCATACGGGTGAAT-3') and EC19
(5'-AAGGATCCACTCATCGTTTACAGCGTGG-3'); 2 mM
MgCl2; and 1.25 U of Taq DNA polymerase
(Promega, Madison, Wis.) in a 1× reaction buffer (50 mM KCl, 10 mM
Tris HCl [pH 8.3]). All reactions were carried out in sterile
HotStart tubes (Molecular Bio-Products, San Diego, Calif.), which allow
separation of the first and second PCR steps by a wax bead.
Amplification cycles included denaturation at 94°C for 30 s,
annealing at 52°C for 1 min, and chain extension at 72°C for 2 min.
The PCR cycle was repeated for 30 cycles, with a final extension of 3 min at 72°C. For the second round of PCR, a 50-µl reaction mixture
similar to that described above was used, except that no DNA template
was added, primer EC19 was replaced with 50 pmol of GE7r
(5'-CCGTATCTCAGTTCCAGTGTG-3'), and 50 more pmol of primer
GE2f was added. The 50-µl mixture was added on top of the wax bead to
separate the first and second reactions. An initial cycle of 94°C for
5 min melted the wax, denatured the DNA, and initiated the subsequent
reactions. Amplification cycles were then run at 94°C for 30 s,
annealing at 60°C for 1 min, and chain extension at 72°C for 2 min.
The PCR cycle was repeated for 30 cycles, with a final extension of 3 min at 72°C. The PCR products were electrophoresed through 1%
agarose gels in Tris-boric acid-EDTA buffer, and the DNA fragments were
visualized by ethidium bromide staining under UV fluorescence.
(iv) Secondary transfusion to recipient dogs.
To further
document the sensitivity of culture and PCR as modalities for the
detection of ehrlichiemia, blood was collected from all infected dogs
and shipped to Fort Dodge Laboratories in Fort Dodge, Iowa. There, 20 ml of blood from each infected control dog in group II was transfused
into a new recipient (n = 4). A 40-ml pooled sample
from four dogs in group III receiving a homologous challenge (10 ml
from each dog) was transfused to two recipients (20 ml each). The same
approach was used for dogs in group IV receiving a heterologous
challenge.
Statistics.
Treatment and challenge inoculation effects were
analyzed by multivariate repeated-measures analysis of variance
(14) with PROC GLM software (version 6-09) from SAS Inc.
(Cary, N.C.). A separate analysis was performed for each physiologic
parameter. A Student-Newman-Keuls comparison procedure at an alpha
level of 0.05 was carried out each time to differentiate significant effects among the groups. The analysis was done separately for times
prior to infection, prior to treatment, following treatment and prior
to challenge, and following challenge. Profile contrasts were used to
detect significant differences in the shape of the parameter response
curves among the experimental groups. The nonparametric Kruskal-Wallis
test was performed on attitudinal scores due to the nonnormality of the
data. Proc NPARIWAY software (version 6.09) from SAS Inc. was used.
 |
RESULTS |
Initial infection.
Prior to infection there were no
significant differences in attitudinal scores, rectal temperature
measurements, or neutrophil or platelet counts among the four groups of
dogs. Despite randomization, prior to and throughout the study there
was a tendency for dogs in groups I and III to have higher mean packed
cell volumes (PCV), which at various time points was significantly
(P < 0.05) lower than those for dogs in groups II and
IV. On the basis of the development of consistent clinical and
hematologic abnormalities (Fig. 1), seroconversion to E. canis antigens (Fig.
2), positive tissue culture results
(Table 1), and PCR detection of E. canis DNA (Table 1; Fig. 3), all 12 dogs in groups II, III, and IV became infected following the initial
inoculation with E. canis Florida. Fever was detected in the
dogs in these three groups between days 14 and 21, and behavioral
scores decreased from 5 to 4 between PIDs 13 and 32. During the
pretreatment period (PIDs 1 to 30), there was a mild decrease in PCVs
and neutrophil counts and a significant decrease in platelet counts
(P = 0.02) among the infected dogs. The platelet count
nadir for the dogs in the three inoculated groups occurred on PID 21 (Fig. 1). There was no significant difference (P > 0.05) in mean PCV, neutrophil count, or platelet count among the dogs
in the three infection groups prior to the initiation of doxycycline
treatment. Morulae were not observed on Wright's-stained blood smears
at any time during the study. E. canis-specific antibodies were detectable in all 12 dogs on PID 14 (reciprocal titers ranged from
20 to 640). Western immunoblotting detected a genus-specific protein of
approximately 30 kDa by PID 29 in all but one dog (dog 150, group II).
Full recognition of ehrlichial proteins, as exemplified by a positive
control serum sample obtained from a chronically infected experimental
dog, was not detected in most dogs until after PID 90. Control sera
consistently recognized 28- through 30-, 32-, 40-, 53-, and 60-kDa
proteins, with variable recognition of 24-, 26-, 27-, and 64-kDa
proteins. Tissue culture isolation of E. canis was
successful in samples from 3 dogs on PID 7, from 10 dogs on PID 14, from all 12 infected dogs on PID 21, and from 7 dogs on PID 29 (Table
1). PCR results were concordant with tissue culture isolation results
except on four occasions when PCR was negative and three occasions when
PCR was positive (Table 1).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Mean platelet counts for dogs in the uninfected control,
infected control, homologous challenge, and heterologous challenge
groups after transfusion of E. canis-infected blood (day 0),
after initiation of doxycycline treatment (day 31), and after challenge
inoculation (day 90).
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Mean microimmunofluorescence antibody (IFA) titers for
dogs in the uninfected control (no seroconversion), infected control,
homologous challenge, and heterologous challenge groups after
transfusion of E. canis-infected blood (day 0), after the
initiation of doxycycline treatment (day 30), and after challenge
inoculation (day 90). The equivalent reciprocal IFA titers are given in
parentheses.
|
|

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 3.
Results of PCR for E. canis detection
demonstrating enhanced sensitivity of the seminested method. (A) By
using first-step primers, a 780-bp PCR product can be visualized in
lane 1 (positive control, cultured E. canis) but not in
lanes 2 to 11 (DNA extracted from EDTA-anticoagulated blood samples
from dogs 2 to 11, respectively). (B) A seminested PCR product yielding
a 220-bp band can be identified for the positive control (lane 1) and
blood samples from dogs 2, 4, 6, 8, 9, and 10 (the same samples tested
in panel A). Lane M, 100-bp DNA ladder (Promega). Numbers on the left
are in base pairs.
|
|
Doxycycline treatment.
Immediately prior to treatment, the
behavioral score was 5 (alert, active, and eating) for all 16 dogs, and
all dogs were afebrile. During the period of treatment, the behavioral
score remained 5 for all 16 dogs. There were no significant differences in rectal temperature measurements, mean hematocrit values, absolute neutrophil counts, or platelet counts.
Documenting therapeutic elimination of E. canis.
Following treatment with doxycycline, tissue culture isolation attempts
and PCR results were negative during the 45-day posttreatment period
(Table 1). During this time period, reciprocal IFA titers decreased
gradually (greater than or equal to a twofold dilution) in 11 of 12 dogs (groups II to IV); 1 dog (dog 149, group IV) maintained a stable
titer. Sera from untreated infected control dogs (group II) developed
protein recognition patterns on Western immunoblots that were similar
to those seen for sera from control dogs by PID 90, with recognition of
24-, 26-, 28- through 30-, 32-, 40-, and 60-kDa proteins, whereas
similar patterns of protein recognition were delayed in the dogs in the
two treatment groups until after challenge (PID 118).
Challenge inoculation and postchallenge period.
With the
exception that the mean platelet counts for dogs in group II were
significantly higher (P = 0.05) than those for dogs in
group III or IV immediately prior to challenge inoculation, there were
no differences among the groups. Following challenge inoculation on PID
90, both challenge groups (groups III and IV) became E. canis culture positive (Table 1). Compared to homologous challenge, heterologous challenge resulted in an enhanced severity of
fever, anemia, neutropenia, and thrombocytopenia and an increased anamnestic serologic response (Fig. 4).
During this period (PIDs 90 to 148), E. canis was detected
by tissue culture on two occasions (dog 153 on PID 111 and dog 152 on
PID 133) and PCR on four occasions (dog 153) among the dogs in the
infected control group. There were no discernible differences in the
Western immunoblot patterns among the three infection groups during the
postchallenge period (PIDs 90 to 148). Despite an anamnestic IFA
serologic response in the groups receiving homologous and heterologous
challenge, no discernible change in the staining intensity or the
number of protein bands was detected by Western immunoblotting in
samples from those groups compared to the staining intensity and number of protein bands in samples from the infected control group.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
Mean PCV, neutrophil and platelet counts, and IFA titers
for dogs in the homologous challenge and heterologous challenge groups
following challenge inoculation (day 90). The equivalent reciprocal IFA
titers are given in parentheses.
|
|
Blood obtained on PID 148 from each of the infected control dogs was
transfused into four healthy recipient dogs. These dogs did not develop
clinical abnormalities or thrombocytopenia or demonstrate
seroconversion to E. canis antigens. Blood obtained on PID
148 from dogs in both the homologous challenge and the heterologous
challenge groups was similarly transfused into eight healthy recipient
dogs. Resulting compatible clinical abnormalities included fever
(rectal temperatures, greater than 39.8°C), thrombocytopenia (platelet counts, below 100,000/µl), and seroconversion to E. canis antigens (reciprocal titers, 5,120). Although it was
expensive and of limited practical utility, administration of blood to
recipient dogs served to support the tissue culture and PCR results
derived during the final stage of this project.
Summarization of the culture and PCR data in Table 1 indicates test
agreement for 56 datum points and test disagreement for 12 datum
points. Agreement between culture and PCR results was found for 56 negative and 17 positive datum points, respectively; culture was
positive and PCR was negative in five instances, whereas culture was
negative and PCR was positive in seven instances.
 |
DISCUSSION |
Doxycycline treatment and the possibility of natural immunity.
When untreated, E. canis infection generally persists in the
presence of extremely high concentrations of antibody to the organism
(3, 9). Therefore, humoral immunity and cell-mediated immunity following natural infection do not usually confer protection against chronic infection. In nature, many dogs remain infected, presumably for years, without developing obvious abnormalities as a
result of the disease (5). Since we are unable to find definitive supportive evidence of spontaneous resolution of E. canis infection in the literature, it is perhaps of importance that all four untreated infected control dogs appeared to eliminate the
infection or, alternatively, suppress the degree of ehrlichiemia to a
level that was not detectable by tissue culture isolation or PCR or by
the transfusion of blood into recipient dogs. This finding may have
important implications, namely, that an E. canis vaccine,
once developed, might potentially confer protective immunity against
the organism.
In a previous study (11), three of five dogs treated for 7 days with doxycycline (10 mg/kg once daily) remained tissue culture positive following treatment, and E. canis DNA could be
amplified from several tissues, including blood, kidney, lymph node,
liver, and spleen, that were collected when the dogs were killed 54 to 59 days following treatment. In contrast, following doxycycline administration at a similar dosage for 14 days in this study, all eight
dogs became culture and PCR negative during the posttreatment period.
Although tissue culture isolation and/or PCR detection of E. canis DNA was intermittent for the untreated infected control group during this same time period, doxycycline appears to have been
uniformly effective in eliminating E. canis infection from the eight treated dogs.
Utility of various techniques for detecting the presence or absence
of E. canis.
During recent years, there has been
increasing interest in the evolving role of Ehrlichia
species as human and veterinary pathogens. Historical difficulties
associated with the isolation of Ehrlichia species in tissue
culture have compromised the design of therapeutic trials and have
limited the number of E. canis isolates available for
comparative microbiologic or immunopathogenic studies. Since tissue
culture isolation of E. canis can require up to 60 days
(11), the technique is of limited clinical utility. Similarly, tissue culture isolation of E. chaffeensis, the
cause of human monocytic ehrlichiosis, is a difficult, laborious, and time-consuming process, known to require as many as 35 (7) or 60 (8) days for the detection of E. chaffeensis morulae.
In an effort to circumvent the difficulties associated with tissue
culture isolation, recent attempts to document E. canis infection in dogs have incorporated antigen detection by enzyme-linked immunosorbent assay (22) or DNA amplification by PCR
(12, 13). Unfortunately, antigen assays may have limited
utility because of variability in antigen detection during the early
stages of experimental E. canis infection (22).
In this study, we attempted to examine the diagnostic utility of
seminested PCR analysis, using EDTA-anticoagulated blood samples that
would be comparable to the type of sample routinely obtained from sick
dogs for the purpose of hematologic examination. As depicted in Fig. 3,
the seminested PCR proved to be considerably more sensitive than the single-step PCR. Recent modifications to the procedure, such as eliminating the necessity of opening the tube to add reagents for the
second step, decreases problems associated with PCR contamination. In
this study there was generally good agreement between tissue culture
and PCR results. In no instance was an uninfected dog found to be
culture or PCR positive. Similar to a previous study (12,
13), tissue culture appeared to be slightly more sensitive than
seminested PCR for the detection of E. canis, particularly during the acute infection period.
Similar to one of the objectives of this study, Iqbal and colleagues
(11-13) compared the sensitivity of PCR with those of tissue culture isolation, IFA testing, and Western immunoblotting with
experimentally infected German shepherd-mixed breed dogs. Unlike this
study, however, Iqbal and colleagues (12, 13) used
single-step PCR analysis and large quantities of blood, potentially as
much as 30 ml, for the extraction of E. canis DNA. The
important influence of variables such as inoculum size and route of
administration and the potentially detrimental effects of tissue
culture passage of inoculum on the course of experimentally induced
canine ehrlichiosis have been emphasized in two recent reports (9,
16). Therefore, differences in several experimental variables,
including age, breed, E. canis strains, source of inocula,
timing and duration of treatment, and the type of samples used for
various tests, make direct comparison of the results of these two
studies somewhat difficult.
In our experience, Western immunoblotting is useful for confirmation of
acute versus chronic E. canis exposure or for clarification of questionable IFA serologic test results (10). In this
study, treatment appeared to alter the pattern of antigenic protein
recognition, with fewer epitopes identified in treated dogs than in
infected control dogs. However, posttreatment immunoblot patterns did
not identify predictable changes that would facilitate confirmation of
the therapeutic elimination of the organism or identify subsequent infection following reexposure to E. canis. In light of our
experience with clinical canine ehrlichiosis and given the relatively
short time span encompassed by this study, Western immunoblotting for E. canis detection appears to have limited applicability as
a diagnostic modality other than to confirm the specificity of an IFA
test result (18).
Severity of disease manifestations after homologous or heterologous
challenge.
Experimental studies performed nearly three decades ago
indicated that prior infection induced minimal protection to homologous E. canis challenge (3). Therefore, conventional
wisdom has suggested that following therapeutic elimination of the
organism, reinfection will result in recurrent but milder disease. In
this study, which used more sensitive culture and molecular detection techniques, dogs that were infected and subsequently cleared of their
infection after treatment with doxycycline were found to develop
ehrlichiemia and disease manifestations following both homologous
challenge and heterologous challenge. Of potential importance,
heterologous challenge resulted in increased disease severity. Although
other factors may have influenced these results, it is possible that
(i) the heterotypic immune response caused enhancement of disease
manifestations or (ii) the NCSU Jake strain of E. canis is
more virulent than the historical Florida strain. These findings also
suggest the possibility that late-stage disease manifestations in
naturally infected dogs may develop only in those instances when the
host is repeatedly exposed to E. canis or when a chronically
infected dog is subsequently exposed to other intracellular pathogens.
Regardless of the interpretation, these results indicate that
variability among E. canis strains, similar to the
experience with E. chaffeensis and E. risticii, may be of importance when comparing the results of experimental infection studies or when developing vaccination strategies for the
prevention of monocytic ehrlichiosis in dogs. Because prevention of
canine monocytic ehrlichiosis through vaccination would provide a
beneficial approach to the prevention of this disease, additional efforts to characterize differences in virulence among E. canis strains appear to be justified.
 |
ACKNOWLEDGMENTS |
This work was supported by the state of North Carolina and by a
grant from Fort Dodge Laboratories.
We thank Kendall Wills Sterling for editorial assistance; David Wilson
for statistical analysis of the data; Cynthia Babineau, Julie Bradley,
and David Corns for technical assistance; Dale Brown for careful
monitoring of the dogs; and the Laboratory Animal Resources staff for
the care of these dogs.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: College of
Veterinary Medicine, North Carolina State University, 4700 Hillsborough St., Raleigh, NC 27606. Phone: (919) 829-4234. Fax: (919) 829-4336. E-mail: Ed_Breitschwerdt{at}ncsu.edu.
 |
REFERENCES |
| 1.
|
Adawa, D. A. Y.,
A. Z. Hassan,
S. U. Abdullah,
A. B. Ogunkoya,
J. B. Adeyanju, and J. E. Okoro.
1992.
Clinical trial of long-acting oxytetracycline and piroxicam in the treatment of canine ehrlichiosis.
Vet. Q.
15:118-120.
|
| 2.
|
Bartsch, R. C., and R. T. Greene.
1996.
Post-therapy antibody titers in dogs with ehrlichiosis: follow-up study on 68 patients treated primarily with tetracycline and/or doxycycline.
J. Vet. Intern. Med.
10:271-274[Medline].
|
| 3.
|
Buhles, W. C.,
D. L. Huxsoll, and M. Ristic.
1974.
Tropical canine pancytopenia: clinical, hematologic, and serologic response of dogs to Ehrlichia canis infection, tetracycline therapy, and challenge inoculation.
J. Infect. Dis.
130:357-367[Medline].
|
| 4.
|
Chaichanasiriwithaya, W.,
Y. Rikihisa,
S. Yamamoto,
S. Reed,
T. B. Crawford,
L. E. Perryman, and G. H. Palmer.
1994.
Antigenic, morphologic and molecular characterization of new Ehrlichia risticii isolates.
J. Clin. Microbiol.
38:3026-3033.
|
| 5.
|
Codner, E. C., and L. L. Farris-Smith.
1986.
Characterization of the subclinical phase of ehrlichiosis in dogs.
J. Am. Vet. Med. Assoc.
189:47-50[Medline].
|
| 6.
|
Davidson, D. E.,
G. S. Dill,
M. Tingpalapong,
S. Premabutra,
P. L. Nguen,
E. H. Stephenson, and M. Ristic.
1978.
Prophylactic and therapeutic use of tetracycline during an epizootic of ehrlichiosis among military dogs.
J. Am. Vet. Med. Assoc.
172:697-700[Medline].
|
| 7.
|
Dawson, J. E.,
B. E. Anderson,
D. B. Fishbein,
J. L. Sanchez,
C. S. Goldsmith,
K. H. Wilson, and C. W. Duntley.
1991.
Isolation and characterization of an Ehrlichia sp. from a patient diagnosed with human ehrlichiosis.
J. Clin. Microbiol.
29:2741-2745[Abstract/Free Full Text].
|
| 8.
|
Dumler, J. S.,
S.-M. Chen,
K. Asanovich,
E. Trigiani,
V. L. Popov, and D. H. Walker.
1995.
Isolation and characterization of a new strain of Ehrlichia chaffeensis from a patient with nearly fatal monocytic ehrlichiosis.
J. Clin. Microbiol.
33:1704-1711[Abstract].
|
| 9.
|
Gaunt, S. D.,
R. E. Corstvet,
C. M. Berry, and B. Brennan.
1996.
Isolation of Ehrlichia canis from dogs following subcutaneous inoculation.
J. Clin. Microbiol.
34:1429-1432[Abstract].
|
| 10.
|
Hegarty, B. C.,
M. G. Levy,
R. F. Gager, and E. B. Breitschwerdt.
1997.
Immunoblot analysis of the immunoglobulin G response to Ehrlichia canis in dogs: an international survey.
J. Vet. Diagn. Invest.
9:32-38[Abstract/Free Full Text].
|
| 11.
|
Iqbal, Z., and Y. Rikihisa.
1994.
Reisolation of Ehrlichia canis from blood and tissues of dogs after doxycycline treatment.
J. Clin. Microbiol.
32:1644-1649[Abstract/Free Full Text].
|
| 12.
|
Iqbal, Z.,
W. Chaichanasiriwithaya, and Y. Rikihisa.
1994.
Comparison of PCR with other tests for early diagnosis of canine ehrlichiosis.
J. Clin. Microbiol.
32:1658-1662[Abstract/Free Full Text].
|
| 13.
|
Iqbal, Z., and Y. Rikihisa.
1994.
Application of the polymerase chain reaction for the detection of Ehrlichia canis in tissues of dogs.
Vet. Microbiol.
42:281-287[Medline].
|
| 14.
|
Johnson, T. A., and D. W. Wichern.
1988.
Applied multivariate statistical analysis, 2nd ed., p. 607.
Prentice-Hall, Inc., Englewood Cliffs, N.J.
|
| 15.
|
Levy, M. G.,
D. Gebhard,
R. Gager, and E. B. Breitschwerdt.
1995.
A newly described canine monocytoid cell line capable of supporting growth of the rickettsial parasite Ehrlichia canis, and useful for examination of host:parasite interactions, abstr., p. 274.
In
Proceedings of the International Union of Immunology Society, 4th International Veterinary Immunology Symposium.
|
| 16.
|
Mathew, J. S.,
S. A. Ewing,
R. W. Barker,
J. C. Fox,
J. E. Dawson,
C. K. Warner,
G. L. Murphy, and K. M. Kocan.
1996.
Attempted transmission of Ehrlichia canis by Rhipicephalus sanguineus after passage in cell culture.
Am. J. Vet. Res.
57:1594-1598[Medline].
|
| 17.
|
Price, J. E., and T. T. Dolan.
1980.
A comparison of the efficacy of imidocarb dipropionate and tetracycline hydrochloride in the treatment of canine ehrlichiosis.
Vet. Rec.
107:275-277[Abstract].
|
| 18.
|
Rikihisa, Y.,
S. A. Ewing, and J. C. Fox.
1994.
Western immunoblot analysis of Ehrlichia chaffeensis, E. canis, or E. ewingii infections in dogs and humans.
J. Clin. Microbiol.
32:2107-2112[Abstract/Free Full Text].
|
| 19.
|
Ristic, M.,
D. L. Huxsoll,
R. M. Weisiger,
P. K. Hildebrandt, and M. B. A. Nyindo.
1972.
Serological diagnosis of tropical canine pancytopenia by indirect immunofluorescence.
Infect. Immun.
6:226-231[Abstract/Free Full Text].
|
| 20.
|
Van Heerden, J., and A. Immelman.
1979.
The use of doxycycline in the treatment of canine ehrlichiosis.
J. S. Afr. Vet. Assoc.
50:241-244[Medline].
|
| 21.
|
Vemulapalli, R.,
B. Biswas, and S. K. Dutta.
1995.
Pathogenic, immunologic, and molecular differences between two Ehrlichia risticii strains.
J. Clin. Microbiol.
33:2987-2992[Abstract].
|
| 22.
|
Waner, T.,
M. Rosner,
S. Harrus,
A. Naveh,
R. Zass, and A. Keysary.
1996.
Detection of ehrlichia antigen in plasma of beagle dogs with experimental acute Ehrlichia canis infection.
Vet. Parasitol.
63:331-335[Medline].
|
Antimicrobial Agents and Chemotherapy, February 1998, p. 362-368, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Schaefer, J. J., Needham, G. R., Bremer, W. G., Rikihisa, Y., Ewing, S. A., Stich, R. W.
(2007). Tick Acquisition of Ehrlichia canis from Dogs Treated with Doxycycline Hyclate. Antimicrob. Agents Chemother.
51: 3394-3396
[Abstract]
[Full Text]
-
Harrus, S., Kenny, M., Miara, L., Aizenberg, I., Waner, T., Shaw, S.
(2004). Comparison of Simultaneous Splenic Sample PCR with Blood Sample PCR for Diagnosis and Treatment of Experimental Ehrlichia canis Infection. Antimicrob. Agents Chemother.
48: 4488-4490
[Abstract]
[Full Text]
-
Levin, M. L., Coble, D. J., Ross, D. E.
(2004). Reinfection with Anaplasma phagocytophilum in BALB/c Mice and Cross-Protection between Two Sympatric Isolates. Infect. Immun.
72: 4723-4730
[Abstract]
[Full Text]
-
Knowles, T. T., Alleman, A. R., Sorenson, H. L., Marciano, D. C., Breitschwerdt, E. B., Harrus, S., Barbet, A. F., Belanger, M.
(2003). Characterization of the Major Antigenic Protein 2 of Ehrlichia canis and Ehrlichia chaffeensis and Its Application for Serodiagnosis of Ehrlichiosis. CVI
10: 520-524
[Abstract]
[Full Text]
-
McBride, J. W., Corstvet, R. E., Gaunt, S. D., Boudreaux, C., Guedry, T., Walker, D. H.
(2003). Kinetics of Antibody Response to Ehrlichia canis Immunoreactive Proteins. Infect. Immun.
71: 2516-2524
[Abstract]
[Full Text]
-
Belanger, M., Sorenson, H. L., France, M. K., Bowie, M. V., Barbet, A. F., Breitschwerdt, E. B., Alleman, A. R.
(2002). Comparison of Serological Detection Methods for Diagnosis of Ehrlichia canis Infections in Dogs. J. Clin. Microbiol.
40: 3506-3508
[Abstract]
[Full Text]
-
Alleman, A. R., McSherry, L. J., Barbet, A. F., Breitschwerdt, E. B., Sorenson, H. L., Bowie, M. V., Belanger, M.
(2001). Recombinant Major Antigenic Protein 2 of Ehrlichia canis: a Potential Diagnostic Tool. J. Clin. Microbiol.
39: 2494-2499
[Abstract]
[Full Text]
-
BEECHING, N.J., HART, C.A., DUERDEN, B.I.
(2000). Tropical and exotic infections: Proceedings of the fifth Liverpool Tropical School Bayer Symposium on Microbial Diseases held on 14 February 1998. J Med Microbiol
49: 5-27
[Full Text]
-
Kordick, S. K., Breitschwerdt, E. B., Hegarty, B. C., Southwick, K. L., Colitz, C. M., Hancock, S. I., Bradley, J. M., Rumbough, R., Mcpherson, J. T., MacCormack, J. N.
(1999). Coinfection with Multiple Tick-Borne Pathogens in a Walker Hound Kennel in North Carolina. J. Clin. Microbiol.
37: 2631-2638
[Abstract]
[Full Text]
-
Breitschwerdt, E. B., Hegarty, B. C., Hancock, S. I.
(1998). Sequential Evaluation of Dogs Naturally Infected with Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia equi, Ehrlichia ewingii, or Bartonella vinsonii. J. Clin. Microbiol.
36: 2645-2651
[Abstract]
[Full Text]